Takeda Pharmaceutical Company Limited
TKPHF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $7,426,910 | $6,621,266 | $6,743,409 | $5,601,525 |
| - Cash | $385,113 | $457,800 | $533,530 | $849,695 |
| + Debt | $4,515,265 | $5,463,391 | $4,382,341 | $4,345,411 |
| Enterprise Value | $11,557,062 | $11,626,857 | $10,592,220 | $9,097,241 |
| Revenue | $4,581,551 | $4,263,762 | $4,027,478 | $3,569,006 |
| % Growth | 7.5% | 5.9% | 12.8% | – |
| Gross Profit | $3,001,334 | $2,832,257 | $2,783,406 | $2,462,160 |
| % Margin | 65.5% | 66.4% | 69.1% | 69% |
| EBITDA | $1,073,791 | $900,328 | $1,156,463 | $1,008,154 |
| % Margin | 23.4% | 21.1% | 28.7% | 28.2% |
| Net Income | $107,928 | $144,067 | $317,017 | $230,059 |
| % Margin | 2.4% | 3.4% | 7.9% | 6.4% |
| EPS Diluted | 67.23 | 91.16 | 201.94 | 145.87 |
| % Growth | -26.3% | -54.9% | 38.4% | – |
| Operating Cash Flow | $1,057,182 | $716,344 | $977,156 | $1,123,105 |
| Capital Expenditures | -$379,625 | -$480,730 | -$633,689 | -$186,037 |
| Free Cash Flow | $677,557 | $235,614 | $343,467 | $937,068 |